Physician profile
Julie L Cantatore-Francis
NPI 1235334913
$74,702.01
in general payments reported to CMS, 2019-2025
39 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 75% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $8,602 · 2021: $8,217 · 2022: $2,114 · 2023: $7,981 · 2024: $21K · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $8,093 · Travel and Lodging: $550 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,000.00 |
| Food and Beverage | $8,093.25 |
| Travel and Lodging | $549.68 |
| Education | $299.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39,466.05 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $23,217.45 | 2023-2024 | Ycanth |
| Incyte Corporation | $1,250.36 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $1,139.82 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,065.60 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $1,001.77 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Genzyme Corporation | $832.65 | 2019-2025 | |
| Medimetriks Pharmaceuticals, INC. | $700.00 | 2019-2022 | |
| Janssen Biotech, INC. | $661.04 | 2021-2025 | Tremfya |
| Galderma Laboratories, L.P. | $629.85 | 2019-2024 | Aklief |
| Sun Pharmaceutical Industries INC. | $626.86 | 2019-2024 | Winlevi, Absorica Ld, Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $592.77 | 2019-2024 | Jublia, Cabtreo, Targretin |
| Mayne Pharma Commercial LLC | $482.87 | 2019-2025 | |
| Leo Pharma INC. | $462.03 | 2019-2025 | Adbry |
| Dermavant Sciences, INC. | $404.90 | 2023-2024 | Vtama |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Cantatore-Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.